Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TET2 |
Variant | D162fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TET2 D162fs results in a change in the amino acid sequence of the Tet2 protein beginning at aa 162 of 2002, likely resulting in premature truncation of the functional protein (UniProt.org). D162fs has not been characterized, however, due to the effects of other truncation mutations downstream of D162 (PMID: 24994606), is predicted to lead to a loss of Tet2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TET2 mutant TET2 inact mut TET2 D162fs |
Transcript | NM_001127208.3 |
gDNA | chr4:g.(105234425_105234426) |
cDNA | c.(484_483) |
Protein | p.D162fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454102.2 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_024454102.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_047415839.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
NM_001127208.2 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_006714242.3 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_005263082.4 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_047415840.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
NM_001127208.3 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_047415842.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_047415841.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_017008319.2 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_024454103.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_006714242.4 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
NM_017628.4 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_024454103.2 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
NM_017628.4 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_047415843.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_017008319.1 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
XM_005263082.3 | chr4:g.(105234425_105234426) | c.(484_483) | p.D162fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|